Cytidine 51-diphosphocholine (Citicoline) in glaucoma: Rationale of its use, current evidence and future perspectives

Gloria Roberti, Lucia Tanga, Manuele Michelessi, Luciano Quaranta, Vincenzo Parisi, Gianluca Manni, Francesco Oddone

Research output: Contribution to journalArticlepeer-review


Cytidine 51-diphosphocholine or citicoline is an endogenous compound that acts in the biosynthetic pathway of phospholipids of cell membranes, particularly phosphatidylcholine, and it is able to increase neurotrasmitters levels in the central nervous system. Citicoline has shown positive effects in Parkinson’s disease and Alzheimer’s disease, as well as in amblyopia. Glaucoma is a neurodegenerative disease currently considered a disease involving ocular and visual brain structures. Neuroprotection has been proposed as a valid therapeutic option for those patients progressing despite a well-controlled intraocular pressure, the main risk factor for the progression of the disease. The aim of this review is to critically summarize the current evidence about the effect of citicoline in glaucoma.

Original languageEnglish
Pages (from-to)28401-28417
Number of pages17
JournalInternational Journal of Molecular Sciences
Issue number12
Publication statusPublished - Nov 30 2015


  • Citicoline
  • Glaucoma
  • Neuroprotection
  • Retinal ganglion cells

ASJC Scopus subject areas

  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Spectroscopy
  • Inorganic Chemistry
  • Catalysis
  • Molecular Biology
  • Computer Science Applications


Dive into the research topics of 'Cytidine 51-diphosphocholine (Citicoline) in glaucoma: Rationale of its use, current evidence and future perspectives'. Together they form a unique fingerprint.

Cite this